Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343693 · ClinicalTrials.gov registry record
MaxAn Post Market Surveillance Validation
A clinical trial of Tumor and Fracture, sponsored by Zimmer Biomet.
- Completed
- Registry status
- 119
- Enrollment target
- 6
- Study locations
NCT01343693 is a study of Tumor and Fracture that has completed, run by Zimmer Biomet. The registered enrollment target is 119 participants, below the 178-participant average among 18 other Tumor trials with a reported enrollment target (33% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT01343693, a study of Tumor and Fracture, has completed, sponsored by Zimmer Biomet.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is being performed to document the outcomes of subjects using our MaxAn Anterior Cervical Plate and assess them for Adjacent level Disease. All subjects will be followed for 2 years.
Study Locations (6)
Alabama
- Montgomery Spine Center - Montgomery
Florida
- Tallahassee Neurological Clinic - Tallahassee
Indiana
- Community Neurosurgery - Indianapolis
Maryland
- Maryland Spine and Brain - Annapolis
North Carolina
- Cary Orthopedics - Cary
Texas
- DFW Center for Spinal Disorders - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2011-06 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343693
The ClinicalTrials.gov registry entry for NCT01343693 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 18 other Tumor trials with a reported enrollment target (33% lower). The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT01343693 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Alabama, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT01343693 about?
NCT01343693 is a clinical study titled "MaxAn Post Market Surveillance Validation". This study is being performed to document the outcomes of subjects using our MaxAn Anterior Cervical Plate and assess them for Adjacent level Disease. All subjects will be followed for 2 years.
What is the current status of trial NCT01343693?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2011-06. Estimated completion is 2018-01.
What conditions does trial NCT01343693 study?
This clinical trial studies the following conditions: Tumor, Fracture, Deformity, DDD.
Who is sponsoring clinical trial NCT01343693?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01343693 being conducted?
This trial has 6 study locations across Alabama, Florida, Indiana, Maryland, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Decoupling Immunotherapy Toxicity and Cancer Response
RECRUITING
-
A Study of Live Tumor Fragments of Surgical Resections
RECRUITING
-
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.